GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Melodiol Global Health Ltd (OTCPK:COPHD) » Definitions » Long-Term Capital Lease Obligation

Melodiol Global Health (Melodiol Global Health) Long-Term Capital Lease Obligation : $0.06 Mil (As of Dec. 2023)


View and export this data going back to 2017. Start your Free Trial

What is Melodiol Global Health Long-Term Capital Lease Obligation?

Melodiol Global Health's Long-Term Capital Lease Obligation for the quarter that ended in Dec. 2023 was $0.06 Mil.

Melodiol Global Health's quarterly Long-Term Capital Lease Obligation stayed the same from Dec. 2022 ($0.00 Mil) to Jun. 2023 ($0.00 Mil) but then increased from Jun. 2023 ($0.00 Mil) to Dec. 2023 ($0.06 Mil).

Melodiol Global Health's annual Long-Term Capital Lease Obligation stayed the same from Dec. 2021 ($0.00 Mil) to Dec. 2022 ($0.00 Mil) but then increased from Dec. 2022 ($0.00 Mil) to Dec. 2023 ($0.06 Mil).


Melodiol Global Health Long-Term Capital Lease Obligation Historical Data

The historical data trend for Melodiol Global Health's Long-Term Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Melodiol Global Health Long-Term Capital Lease Obligation Chart

Melodiol Global Health Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Long-Term Capital Lease Obligation
Get a 7-Day Free Trial - - - - 0.06

Melodiol Global Health Semi-Annual Data
Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Long-Term Capital Lease Obligation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - 0.06

Melodiol Global Health  (OTCPK:COPHD) Long-Term Capital Lease Obligation Explanation

Long-Term Capital Lease Obligation are the amount due for long-term asset lease agreements that are nearly equivalent to asset purchases. Capital lease obligations are installment payments that constitute a payment of principal plus interest for the capital lease. The Short-Term Capital Lease Obligation is the portion of a Long-Term Capital Lease Obligation that is due over the next year.

Under US Generally Accepted Accounting Principles (GAAP), a capital lease is essentially equivalent to a purchase by the lessee if it meets the following criteria:

1. Ownership of the asset is transferred to the lessee at the end of the lease term;
2. The lease contains a bargain purchase option to buy the equipment at less than fair market value;
3. The lease term equals or exceeds 75% of the asset's estimated useful life;
4. The present value of the lease payments equals or exceeds 90% of the total original cost of the equipment.

Melodiol Global Health Long-Term Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of Melodiol Global Health's Long-Term Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.


Melodiol Global Health (Melodiol Global Health) Business Description

Traded in Other Exchanges
Address
145 Stirling Highway, Suite 5 CPC, Nedlands, WA, AUS, 6009
Melodiol Global Health Ltd is engaged in developing, registering, and commercialization of pharmaceutical-grade cannabis and hemp-based nutraceutical products and treatments for human and animal health. Its brands include Mernova: A licensed producer of cannabis products in Canada for sale under the Ritual brand banner. Sierra Sage Herbs: US-based developer of plant-based, beauty, and personal care brands Green Goo, Southern Butter, and Good Goo. impACTIVE: CBD topical products for athletes. Halucenex: Clinical stage psychedelics research and development operation. Creso Pharma Switzerland: CBD-related research, development, and commercialization.

Melodiol Global Health (Melodiol Global Health) Headlines

From GuruFocus

Sierra Sage Herbs Acquired By Creso Pharma

By PRNewswire PRNewswire 02-07-2022